NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE45867 Query DataSets for GSE45867
Status Public on Dec 30, 2013
Title Effects of tocilizumab versus methotrexate therapy on gene expression profiles in the early rheumatoid arthrtis synovium
Organism Homo sapiens
Experiment type Expression profiling by array
Summary Rheumatoid arthritis (RA) is a chronic, systemic autoimmune inflammatory disease that is characterized by the presence of inflammatory cytokines, including interleukin-6 (IL-6). Here, we investigated the global molecular effects of Tocilizumab, an approved humanized anti-IL6 Receptor antibody, versus Methotrexate therapy, in synovial biopsy samples collected prospectively in early RA before and 12 weeks after administration of the drug. The results were compared with our previous data, generated in prospective cohorts of Adalimumab- and Rituximab-treated (Methotrexate- and anti-TNF-resistant, respectively) RA patients.
We found that Tocilizumab induces a significant down-regulation of genes included in specific pathways: cytokines & chemokines (e.g. IL-6, IL-7, IL-22, CCL8, CCL11, CCL13, CCL19, CCL20), and T cell activation. By contrast, Tocilizumab induces a significant up-regulation of genes associated with healing processes. These effects are significantly more pronounced as compared to Methotrexate, Rituximab, or Adalimumab therapies. By opposition to the effects of Adalimumab, Tocilizumab therapy does not induce a decreased expression of genes involved in cell proliferation.
 
Overall design Paired synovial biopsy samples were obtained from the affected knee of early RA patients before and 12 weeks after initiation of Tocilizumab (n=12) or Methotrexate (n=8) therapy. SDAI remission criteria were computed prospectively before, 3 months and 6 months after administration of the drugs and patients’ responses were defined according to their SDAI remission status at 6 months. Gene expression studies were performed using GeneChip Human Genome U133 Plus 2.0 arrays.
 
Contributor(s) Ducreux J, Durez P, Toukap AN, Houssiau FA, Lauwerys BR
Citation(s) 24449571, 25927832
Submission date Apr 08, 2013
Last update date Aug 09, 2019
Contact name Bernard Robert Lauwerys
E-mail(s) Bernard.Lauwerys@uclouvain.be
Phone +3227645391
Organization name Université catholique de Louvain
Department Institut de Recherches Expérimentales et Cliniques
Lab Pôle de pathologies rhumatismales et systémiques
Street address Avenue Hippocrate 10
City Brussels
ZIP/Postal code 1200
Country Belgium
 
Platforms (1)
GPL570 [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
Samples (40)
GSM1116933 Synovial tissue prior to Tocilizumab therapy, repl 1
GSM1116934 Synovial tissue after to Tocilizumab therapy, repl 1
GSM1116935 Synovial tissue prior to Tocilizumab therapy, repl 2
Relations
BioProject PRJNA196517

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE45867_RAW.tar 198.1 Mb (http)(custom) TAR (of CEL)
Raw data provided as supplementary file
Processed data included within Sample table

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap